Zymeworks Inc.
About Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $106.0M
- Net income
- -$81.1M
- Total assets
- $346.5M
- Market cap
- $1.8B
- Operating margin
- -87.3%
- Net margin
- -76.6%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $106.0M
- Operating expenses
- $198.5M
- Operating income
- -$92.5M
- Income tax
- $1.4M
- Net income
- -$81.1M
- EPS (basic)
- $-1.08
- EPS (diluted)
- $-1.08
Balance sheet
- Total assets
- $346.5M
- Current assets
- $248.8M
- Total liabilities
- $78.0M
- Current liabilities
- $42.3M
- Shareholders’ equity
- $268.5M
Cash flow
- Operating cash flow
- -$33.0M
- Investing cash flow
- $26.7M
- Financing cash flow
- -$18.6M
- Net cash flow
- -$24.9M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.8B
- EPS (diluted)
- $-1.08
- Shares outstanding
- 73.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 28, 2017
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $81.1M in FY2025.
- Revenue grew 297% from FY2021 to FY2025.
- Trading 16% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Zymeworks Inc..
Write a review
News about Zymeworks Inc.
News & sentiment via Polygon.io
